Russell Investments Group Ltd. increased its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 222.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,724 shares of the company's stock after acquiring an additional 66,771 shares during the period. Russell Investments Group Ltd. owned about 0.09% of Arcus Biosciences worth $759,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock valued at $52,499,000 after purchasing an additional 1,298,584 shares in the last quarter. Woodline Partners LP raised its position in Arcus Biosciences by 1.3% in the 4th quarter. Woodline Partners LP now owns 3,523,937 shares of the company's stock valued at $52,471,000 after purchasing an additional 45,497 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Arcus Biosciences by 11.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock valued at $25,348,000 after purchasing an additional 178,351 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in Arcus Biosciences in the 4th quarter valued at about $23,857,000. Finally, Ameriprise Financial Inc. raised its position in Arcus Biosciences by 17.3% in the 4th quarter. Ameriprise Financial Inc. now owns 1,547,591 shares of the company's stock valued at $23,044,000 after purchasing an additional 228,325 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have issued reports on RCUS. Wall Street Zen raised Arcus Biosciences from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 9th. The Goldman Sachs Group reduced their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Wedbush reiterated an "outperform" rating and issued a $33.00 price objective on shares of Arcus Biosciences in a report on Wednesday, May 7th. Wells Fargo & Company dropped their price objective on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Finally, Morgan Stanley dropped their price objective on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Arcus Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $21.14.
Get Our Latest Stock Analysis on Arcus Biosciences
Arcus Biosciences Stock Performance
NYSE:RCUS traded down $0.07 during mid-day trading on Thursday, reaching $11.57. 1,151,157 shares of the stock were exchanged, compared to its average volume of 733,633. The company has a 50 day simple moving average of $9.63 and a 200-day simple moving average of $9.13. The stock has a market capitalization of $1.23 billion, a P/E ratio of -3.65 and a beta of 0.83. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $18.98.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. The firm had revenue of $160.00 million for the quarter, compared to the consensus estimate of $32.86 million. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.The firm's quarterly revenue was up 310.3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.02) EPS. Analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.
Arcus Biosciences Profile
(
Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
